RBC Capital analyst Brian Abrahams maintained a Hold rating on Incyte (INCY – Research Report) on January 21 and set a price target of $70.00.

In a report released on January 20, Rishi Jaluria from RBC Capital maintained a Buy rating on Clearwater Analytics Holdings (CWAN – Research ...

CF Industries Holdings, Inc. (CF) stock saw a decline, ending the day at $93.66 which represents a decrease of $-3.35 or -3.45% from the prior close of $97.01. The stock opened at $95.5 and touched a ...

RBC Capital Markets sized up Shopify Inc. (NYSE:SHOP) ahead of the company's Q4 earnings report due out in a few weeks. Analyst Paul Treiber said data from several third-party sources indicates ...

RBC Capital Markets maintained its Outperform rating on Shopify (NYSE:SHOP) with a steadfast price target of $130.00, positioning it between the analyst range of $78 to $145. RBC Capital's analysis ...

However, its 2025 costs and capital expenditure guidance exceeded analyst expectations as well as its own previous guidance. For full-year 2025, Hochschild expects capital expenditure between $197 ...

Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and ...

Fintel reports that on January 7, 2025, RBC Capital upgraded their outlook for Carvana (LSE:0A79) from Sector Perform to Outperform. There are 997 funds or institutions reporting positions in Carvana.

Acknowledging that there is skepticism surrounding its business model and ability to sustain profitability targets, RBC Capital joins the growing list of bulls in support of Carvana, raising its ...

Fintel reports that on January 6, 2025, RBC Capital downgraded their outlook for T-Mobile US (BRSE:TMUS) from Outperform to Sector Perform. There are 2,603 funds or institutions reporting ...

Investing.com -- RBC Capital Markets on Monday upgraded Carvana (NYSE:CVNA) shares to Outperform, and lifted the target price to $280 from $270. According to the firm’s analysts, following ...

On Thursday, RBC Capital Markets adjusted their stance on Neumora Therapeutics (NASDAQ:NMRA), downgrading the stock from an Outperform to a Sector Perform rating. This change comes in the wake of ...